Diabetology, published by MDPI, is an esteemed Open Access journal dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. Launched in 2020, this journal has quickly established itself, achieving a Category Quartile ranking of Q3 in Endocrinology, Diabetes and Metabolism and Q2 in Internal Medicine as of 2023. With a commitment to disseminating high-quality research, Diabetology provides an important platform for scientists, healthcare professionals, and students to contribute to the growing body of knowledge regarding diabetes and related conditions. Operating from its headquarters in Basel, Switzerland, the journal embraces an open access model, ensuring that research is accessible worldwide, fostering collaboration and innovation in this critical area of health. As the global diabetic epidemic continues to evolve, Diabetology plays a vital role in informing and educating stakeholders through rigorous peer-reviewed articles while boosting its visibility with impressive Scopus rankings. This journal is not only a resource for current data and findings but also a hub for groundbreaking studies that strive to improve patient outcomes and inform public health policies.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.

Lancet Diabetes & Endocrinology is a premier peer-reviewed journal, published by Elsevier Science Inc, dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Established in 2013, this journal has quickly ascended to a position of notable prestige, reflected in its prestigious Q1 rank across various categories, including Endocrinology, Internal Medicine, and Diabetes & Metabolism. With an impressive impact factor and Scopus rankings placing it in the 99th percentile of its field, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal aims to disseminate high-quality research covering clinical and experimental aspects of metabolic and endocrine disorders, making it an indispensable tool for those looking to stay at the forefront of these rapidly evolving fields. With its focus on innovative depth and cutting-edge studies, Lancet Diabetes & Endocrinology continually fosters an international dialogue critical for advancements in diabetes and endocrinology.

Current Diabetes Reports is a leading academic journal published by CURRENT MEDICINE GROUP, dedicated to advancing research and clinical practices in the field of diabetes and endocrinology. With an impressive impact factor and ranked in the prestigious Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 2001 and converging years up to 2024, Current Diabetes Reports aims to disseminate high-quality, peer-reviewed research articles, reviews, and clinical studies that address the multifaceted challenges of diabetes management and treatment. As it continues to thrive within a robust international community, the journal provides critical insights that are essential for improving patient outcomes and informing public health policies in the United States and beyond.

Current Obesity Reports, an esteemed journal published by SPRINGER, serves as a pivotal platform for scholars and practitioners in the field of obesity research. With its ISSN of 2162-4968, this journal has been recognized within the competitive landscape of Medicine & Internal Medicine, achieving a commendable Scopus rank of #11 out of 167, placing it in the top 93rd percentile. Launched in 2012 and covering critical developments in obesity up to 2024, this journal synthesizes innovative research, evidence-based practices, and comprehensive reviews that cater to a diverse audience, from researchers to public health professionals. While currently not offering open access options, it remains dedicated to advancing knowledge and fostering discussions that address the multifaceted issues related to obesity, its public health implications, and treatment methodologies. For those involved in tackling obesity challenges, Current Obesity Reports stands as a vital resource, contributing significantly to the discourse and scholarship in the field.

The Journal of Diabetology, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 2010, this Open Access journal has provided researchers and healthcare professionals with a wealth of knowledge through rigorous peer-reviewed articles that cover clinical research, epidemiology, and innovative treatment strategies. With an E-ISSN of 2078-7685 and a commitment to disseminating high-quality scientific work, the journal plays a pivotal role in contributing to the global discourse on diabetes care and prevention. Its dedication to accessibility enhances its impact on both established scholars and emerging researchers seeking to make meaningful contributions in the field. By fostering a collaborative environment, the Journal of Diabetology aims to bridge the gap between research and practical implementation, ultimately improving outcomes for individuals affected by diabetes.

DIABETES RESEARCH AND CLINICAL PRACTICE, published by Elsevier Ireland Ltd, is a leading peer-reviewed journal in the realms of endocrinology, diabetes, and internal medicine. With a prestigious Q1 classification across several categories, including Endocrinology, Diabetes and Metabolism, and Internal Medicine, this journal is recognized for its impactful contributions to advancing knowledge and clinical practice in diabetes care, boasting an impressive impact factor that underscores its significance in the academic community. Spanning from 1985 to 2024, this journal not only disseminates high-quality research but also serves as a critical resource for healthcare professionals, researchers, and students alike who are focused on addressing the global diabetes epidemic. With its comprehensive scope and commitment to fostering innovative findings, DIABETES RESEARCH AND CLINICAL PRACTICE remains at the forefront of its field, fostering collaboration and discovery to improve patient outcomes.

The Journal of Obesity & Metabolic Syndrome, published by the Korean Society for the Study of Obesity, is a premier, open access journal that has been championing research in the realms of endocrinology, diabetes, and metabolism since its inception in 2012. With an ISSN of 2508-6235 and an E-ISSN of 2508-7576, this journal has quickly established itself as a leading publication, currently ranked in the Q1 category within its field and occupying the 46th position out of 244 in Scopus' Medicine category, with an impressive 81st percentile ranking. The journal serves as a vital platform for disseminating high-quality research and innovative findings related to obesity and metabolic disorders, fostering collaboration among researchers, healthcare professionals, and students dedicated to advancing knowledge and treatment strategies. For those interested in contributing or gaining access to cutting-edge research, the journal emphasizes its commitment to open access principles by providing unrestricted access to its content, thereby enhancing the visibility and impact of studies within the global scientific community.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, published by the Endocrine Society, stands as a premier academic journal within the field of endocrinology, diabetes, and metabolism. With a legacy spanning from 1941 to 2024, this journal is distinguished by its significant impact factor, ranking in the Q1 category across multiple related disciplines including biochemistry, clinical biochemistry, and medicine. This esteemed journal, ISSN 0021-972X and E-ISSN 1945-7197, is backed by rigorous peer review, ensuring the publication of high-quality research that contributes to the advancement of clinical practices and scientific knowledge. With a commendable Scopus ranking, positioned in the top percentile of multiple categories, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM serves as an essential resource for researchers, professionals, and students who seek to stay informed about the latest findings and innovations in endocrine research. The journal enriches the existing body of knowledge and fosters discussion among scholars and practitioners alike, solidifying its crucial role in the ongoing discourse in endocrinology and metabolic health.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.